New phase iib/iii clinical data demonstrates over three years of continuous treatment with oral blarcamesine to significantly benefit early alzheimer's disease patients

Topline attention-ad trial: patients showed improved cognition and function over three years delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation blarcamesine exhibited a favorable safety profile with no treatment-related deaths new york, jan. 13, 2025 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company focused on developing innovative treatments for alzheimer's disease, parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including rett syndrome, and other central nervous system (cns) disorders, today announced that over three years of continuous treatment with blarcamesine (anavex®2-73) demonstrated significantly reduced clinical decline showing continued clinically and meaningful benefit for early alzheimer's disease patients. no new safety findings have been observed with continued blarcamesine treatment over three (3) years with good comparative safety profile and no associated neuroimaging adverse events.
AVXL Ratings Summary
AVXL Quant Ranking